---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-039267"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:47:14.523241+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Structure Therapeutics reports Q4 2022 net loss $11.9M; GSBR-1290 Phase 1b dosing complete

## Summary
- Completed dosing of GSBR-1290 Phase 1b in healthy overweight volunteers; topline data from Phase 1b and Phase 2a expected 2H 2023.
- Completed $185.3M upsized IPO in Feb 2023; net proceeds ~$166.7M; cash position $249.4M as of Feb 28, 2023.
- Cash, cash equivalents and marketable securities $90.8M at Dec 31, 2022; expects to fund operations through end of 2025.
- Net loss $11.9M Q4 2022 vs $13.4M Q4 2021; full year net loss $51.3M vs $38.0M in 2021.
- R&D expenses $8.4M Q4 2022, $36.2M full year; G&A $4.6M Q4, $16.4M full year.

## SEC filing metadata
- accession: 0001104659-23-039267
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465923039267/0001104659-23-039267-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465923039267/tm2310702d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-039267
- JSON: https://secwatch.observer/filing/0001104659-23-039267.json
- Plain text: https://secwatch.observer/filing/0001104659-23-039267.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.